BindingDB logo
myBDB logout

62 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26810316 29 Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis.EBI Merck Research Laboratories
25254640 64 Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.EBI Syntrix Biosystems
24075145 17 Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.EBI GlaxoSmithKline Medicines Research Centre
23403082 28 Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.EBI Broad Institute of MIT and Harvard
15922596 7 Novel phomactin analogues as PAF receptor ligands.EBI The University of Nottingham
16220969 219 Designed multiple ligands. An emerging drug discovery paradigm.EBI Organon Laboratories
8978857 17 Structure-activity relationships of phomactin derivatives as platelet activating factor antagonists.EBI Sankyo Co. Ltd
7707324 22 Synthesis of alkyl chain-modified ether lipids and evaluation of their in vitro cytotoxicity.EBI Laboratorios Menarini SA
7658439 43 Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.EBI Pfizer Central Research
7658438 22 Novel antagonists of platelet-activating factor. 1. Synthesis and structure-activity relationships of benzodiazepine and benzazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.EBI Pfizer Central Research
8027984 93 3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists.EBI Abbott Laboratories
8478911 48 Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.EBI Universit£ Paris 7
1578493 103 Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.EBI American Cyanamid Company
1433215 88 (Pyridylcyanomethyl)piperazines as orally active PAF antagonists.EBI J. Uriach& C£a.S.A.
1404229 15 Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)-phenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent orally active platelet-activating factor (PAF) antagonist and its water-soluble prodrug phosphate ester.EBI Merck Research Laboratories
1507200 40 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.EBI Pfizer Central Research
2175357 11 4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists.EBI ALTER, S.A.
2909744 27 Platelet activating factor antagonists: synthesis and structure-activity studies of novel PAF analogues modified in the phosphorylcholine moiety.EBI Takeda Chemical Industries Ltd.
3027330 7 Structure-activity relationships of kadsurenone analogues.EBI TBA
9871752 4 A 3D-QSAR study on ginkgolides and their analogues with comparative molecular field analysis.EBI Chinese Academy of Sciences
 19 Cyclic ether acetal platelet activating factor (PAF) receptor antagonists II: imidazo[4,5-c]pyridyl derivativesEBI TBA
 28 Cyclic ether acetal platelet activating factor (PAF) receptor antagonists I: 3-pyridyl derivativesEBI TBA
 8 A partial pharmacophore for the platelet activating factor (PAF) receptorEBI TBA
 4 Synthesis and biological activity of the platelet-activating factor antagonist ()-trans-2-(3-methoxy-4-phenylsulfonylethoxy-5-n-propylsulfonylphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-671,284) and its analogsEBI TBA
 7 Synthesis and biological activity of MK 287 (L-680,573): a potent, specific and orally active paf receptor antagonistEBI TBA
 42 Cmi-206: A potent dual platelet activating factor antagonist and 5-lipoxygenase inhibitorEBI TBA
 17 Enantiodifferentiation of dihydropyridine PAF antagonistsEBI TBA
 34 Synthesis and evaluation of water soluble indole pyrrolothiazole paf antagonistsEBI TBA
 4 Synthesis of active metabolites of indole pyrrolothiazole paf antagonistsEBI TBA
 30 Discovery and optimization of indole pyrrolothiazole paf antagonistsEBI TBA
 22 The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonists.EBI TBA
 33 Synthesis and bioactivities of heterocyclic lipids as PAF antagonists. 2EBI TBA
 51 Synthesis and bioactivities of heterocyclic lipids as PAF antagonists. 1EBI TBA
 13 Synthesis of bicyclic thiazolidine PAF antagonistsEBI TBA
16722655 28 Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.EBI Pfizer Global Research & Development
12570381 15 Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists.EBI Columbia University
12190325 13 Ginkgolide derivatives for photolabeling studies: preparation and pharmacological evaluation.EBI Columbia University
9651167 20 In vitro platelet-activating factor receptor binding inhibitory activity of pinusolide derivatives: a structure-activity study.EBI Seoul National University
9599246 28 (+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist.EBI University of Virginia
9438024 94 Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.EBI Abbott Laboratories
8496938 38 Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.EBI American Cyanamid Company
8411016 76 Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.EBI J. Uriach & Cía, S.A.
8230095 11 Structural modification of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinoline platelet activating factor receptor antagonists.EBI Sandoz Research Institute
7830265 34 Antitumor activity of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinolines.EBI Sandoz Research Institute
7783144 10 Development of a novel series of trialkoxyaryl derivatives as specific and competitive antagonists of platelet activating factor.EBI Wellcome Research Laboratories
3339617 34 Pyrido[2,1-b]quinazolinecarboxamide derivatives as platelet activating factor antagonists.EBI Hoffmann-La Roche Inc.
3020247 10 Conformation and activity of tetrahydrofuran lignans and analogues as specific platelet activating factor antagonists.EBI TBA
2754709 57 Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.EBI Roche Research Center
2754708 27 Biphenylcarboxamide derivatives as antagonists of platelet-activating factor.EBI Roche Research Center
2170651 13 Propenyl carboxamide derivatives as antagonists of platelet activating factor.EBI Hoffmann-La Roche Inc.
2016721 35 Thienotriazolodiazepines as platelet-activating factor antagonists. Steric limitations for the substituent in position 2.EBI Roche Research Center
2002463 78 Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.EBI Roche Research Center
1992139 87 Disubstituted tetrahydrofurans and dioxolanes and PAF antagonists.EBI J. Uriach & Cía.S.A.
1671420 49 Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.EBI Schering-Plough Corporation
1542094 20 4-substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists.EBI J. Uriach & Cía.S.A.
1317924 28 Synthesis and structure-activity relationships of a series of novel benzopyran-containing platelet activating factor antagonists.EBI Abbott Laboratories
15798001 56 Inhibitory effect of the 4-aminotetrahydroquinoline derivatives, selective chemoattractant receptor-homologous molecule expressed on T helper 2 cell antagonists, on eosinophil migration induced by prostaglandin D2.BDB Kyowa Hakko Kogyo Co., Ltd.
15131245 86 SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.BDB Sanofi-Synthelabo Recherche
12721338 61 N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.BDB Pudue Pharma Discovery Research
9454810 72 SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.BDB Sanofi Recherche
2841449 9 Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.BDB Merck Sharp & Dohme Research Laboratories
2156995 27 Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets.BDB Rhone-Poulenc Sante